Table 1.
Characteristics of study participants from two clinical trials
| Pharmacokinetic (n = 37) | Pharmacodynamic (n = 227) | |
|---|---|---|
| Age, years | 53.3 ± 11.7 | 50.4 ± 9.4 |
| Males | 19 (51.4) | 104 (45.8) |
| Race | ||
| Black/African American | 12 (32.4) | 84 (37.0) |
| Asian | 1 (2.7) | 1 (0.4) |
| White/European American | 24 (64.9) | 139 (61.2) |
| Other | 0 | 3 (1.3) |
| BMI, kg/m2 | 30.4 ± 4.7 | 30.6 ± 5.3 |
| CYP2D6 ASa | ||
| 0 | 4 (10.8) | 12 (5.3) |
| 0.25–0.75 | 3 (8.1) | 17 (7.5) |
| 1 | 7 (18.9) | 69 (30.4) |
| 1.25–1.5 | 7 (18.9) | 38 (16.7) |
| 2–2.25 | 14 (37.8) | 82 (36.1) |
| > 2.25 | 2 (5.4) | 9 (4.0) |
| CYP2D6 AS + rs5758550b | ||
| 0 | 4 (10.8) | 12 (5.3) |
| 0.25–0.75 | 5 (13.5) | 25 (11.0) |
| 1 | 8 (21.6) | 66 (29.1) |
| 1.25–1.5 | 7 (18.9) | 43 (18.9) |
| 2–2.25 | 12 (32.4) | 68 (30.0) |
| > 2.25 | 1 (2.7) | 8 (3.5) |
| Unknown | 0 | 5 (2.2) |
Data are presented as mean ± SD or n (%).
AS, activity score; BMI, body mass index.
a
AS derived from CYP2D6 genotype and phenoconversion.
b
AS derived from CYP2D6 genotype, phenoconversion, and rs5758550.